Mineralys Therapeutics
MLYS
219 hedge funds and large institutions have $2.42B invested in Mineralys Therapeutics in 2026 Q3 according to their latest regulatory filings, with 35 funds opening new positions, 84 increasing their positions, 64 reducing their positions, and 36 closing their positions.
576% more call options, than puts
Call options by funds: $50.7M | Put options by funds: $7.5M
31% more repeat investments, than reductions
Existing positions increased: 84 | Existing positions reduced: 64
3% less first-time investments, than exits
New positions opened: 35 | Existing positions closed: 36
3% less funds holding
Funds holding: 225 → 219 (-6)
11.28% less ownership
Funds ownership: 120.96% → 109.68% (-11%)
22% less capital inflows, than outflows
Capital inflows: $250M | Capital outflows: $319M
22% less funds holding in top 10
Funds holding in top 10: 9 → 7 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$34.6M |
| 2 |
Woodline Partners
San Francisco,
California
|
+$26.4M |
| 3 |
Suvretta Capital Management
New York
|
+$25.2M |
| 4 |
Capital World Investors
Los Angeles,
California
|
+$15.6M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$9.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$34.4M |
| 2 |
Logos Global Management
San Francisco,
California
|
-$28.3M |
| 3 |
Tudor Investment Corp
Stamford,
Connecticut
|
-$18.6M |
| 4 |
Troluce Capital Advisors
Dorado,
Puerto Rico
|
-$18.1M |
| 5 |
OrbiMed
New York
|
-$17.8M |
MLYS Hedge Fund Activity: Q3 2026 in Review
219 of the 8,227 institutional investors tracked by Wall St. Rank reported a position in Mineralys Therapeutics (MLYS) for Q3 2026, worth a combined $2.42B — down 9.8% from $2.69B a quarter earlier.
Sellers outnumbered buyers: 36 funds closed out of MLYS and 35 opened new positions — a net loss of 1 holder — while 64 trimmed existing stakes and 84 added.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $34.6M. The largest seller was State Street, cutting an estimated $34.4M.
- 219 institutional investors held Mineralys Therapeutics (MLYS) as of Q3 2026, down from 225 in Q2 2026.
- Funds reported $2.42B of Mineralys Therapeutics stock for Q3 2026, down 9.8% quarter-over-quarter.
- 35 funds opened new Mineralys Therapeutics positions in Q3 2026 and 36 closed out, a net change of -1 holder.
- The largest Mineralys Therapeutics buyer in Q3 2026 was Point72 Asset Management, an estimated $34.6M added.
- The largest Mineralys Therapeutics seller in Q3 2026 was State Street, an estimated $34.4M sold.
Based on aggregated 13F filings for Q3 2026.